Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency (GAUSS)

NCT06237205 is registered in ClinicalTrials.gov with Korea University Anam Hospital as lead sponsor.

NCT NCT06237205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06237205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency (GAUSS)
Lead sponsor
Korea University Anam Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 27, 2024
Completion date
June 30, 2027
Enrollment
33 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy